ITCI: חוב כולל להון Intra-Cellular

Intra-Cellular Therapies (ITCI) generates revenue from the supply of Caplyta to psychiatric centers for the treatment of bipolar disorder and schizophrenia, receiving payments from insurers. The company is pursuing growth through B2B channels in US hospitals and the search for new medical applications for the drug. This chart reflecting the total debt-to-equity ratio at 0.01 highlights the financial profile amid a dependence on a single product and insurance coverage risks.

The stable debt-to-equity ratio of Intra-Cellular Therapies (ITCI) confirms financial resilience as the company expands its list of medical indications and competes for psychiatrist loyalty. This ratio, calculated as total liabilities divided by equity, measures the business's dependence on creditors, where low values minimize default risks amid rising rates and provide a safety buffer for investments in clinical trials.